Elisabeth Kogan

Dexcel Pharma Technologies Ltd. develops, manufactures and markets branded and generic pharmaceuticals. Its core products include Deximune, PerioChip, and Omeprazole delayed released tablet. The company was founded by Dan Oren in 1968 and is headquartered in Or Akiva, Israel.

Life Technologies Corp. provides products in the areas of scientific research, genetic analysis and applied sciences. Its brands include Invitrogen, Applied Biosystems, Gibco, Molecular Probes, Noves, Ambion and Ion Torrent. The firm’s portfolio includes the most cited products and technologies in qPCR, capillary electrophoresis sequencing, nextgeneration sequencing, molecular diagnostics, forensics, cell culture and analysis, and agriculture research. The company was founded on November 21, 2008 and is headquartered in Carlsbad, CA.

FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona.

Fondation Fondamental is a research organization that focuses on mental illnesses. The private company is based in Creteil, France. The French company's mission is to advance research in this field and help reduce the impact of mental illnesses.

Part of Pfizer Inc., Jouveinal is a French company that manufactures and markets pharmaceuticals, consumer health care products, and confectionery. The company is located in France. Jouveinal was acquired by Warner-Lambert Co. on May 21, 1997.

LNC Therapeutics SA operates as a research and development company that designs and develops medical food formulas. It's develop therapeutic solutions for metabolic and cardiometabolic disorders. The firm also designs and develops formulas for obesity and pre-diabetes sickness. Its products include Stablor, Bariamed, and Fertimed. It encompass serious game, patient community, and support tools: BariaSpoon and BariaFork. The company was founded by Jérôme Théron and Claude Vincent on October 29, 2010 and is headquartered in Bordeaux, France.

Kriya Therapeutics, Inc. designs and develops transformative new treatments for prevalent and severe chronic diseases. The company was founded by Shankar Ramaswamy and Roger Jeffs and is headquartered in Redwood City, CA.

Roivant Sciences, Inc. operates as a pharmaceutical firm. It develops and markets drugs. The firm specializes in uterine fibroids, endometriosis, prostate cancer, diabetes, and pulmonary arterial hypertension. The company was founded by Vivek Ramaswamy in 2014 and is headquartered in New York, NY.

Moleac Pte Ltd. develops and distributes biopharmaceutical products. It operates as a bio-pharmaceutical company that develops new medicines for the unmet needs of patients suffering from neurological, cardio-vascular and aging conditions. The firm's flagship product NeuroAiD, helps patients recover faster and better from stroke disabilities. The company was founded by David Picard and Marc Vasseur in 2003 and is headquartered in Singapore.

The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.

Part of Thales SA, Gemplus is a digital identity and French security company that provides identity management and data protection technologies to businesses and governments. The company's solutions help facilitate secure digital interactions, such as fund exchanges for banks, cross-border travel for individuals, and smarter energy management. All relevant product and service information can be found on their website under the Thales Digital Identity & Security section.

Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France.

Orano SA engages engages in the provision of nuclear fuel cycle products and services. It operates in the following business segments: Mining, Conversion, Enrichment, Recycling, Decommissioning, Supporting operations, Engineering, Nuclear packages and services and, Nuclear medicine. The company was founded on November 6, 1984 and is headquartered in Chatillon, France.

Mirion Technologies (US), Inc. engages in the provision of nuclear measurement and detection systems. It offers measurement and enterprise, calibration, customer training programs, installation, product support and repairs, consulting, and instadose dosimetry services. The company was founded in December 2005 and is headquartered in San Ramon, CA.

Dexcel Pharma Ltd. develop, manufacture and market value-added branded and generic pharmaceuticals. The company was founded by Dan Oren in 1968 and is headquartered in Northamptonshire, the United Kingdom.

Biolog-id SAS develops radio frequency identification electronic tags. It is a designer-integrator specializing in the development of traceability solutions for health products, such as labile blood products (packed red blood cells, platelets, therapeutic plasma), plasma for fractionation and cancer chemotherapy. The company was founded in 1981 and is headquartered in Paris, France.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.